Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023
July 27, 2023 16:04 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, July 27, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted...
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
June 26, 2023 16:05 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, June 26, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Presents Highlights from Clinical Update
June 10, 2023 12:00 ET
|
Aptose Biosciences, Inc.
Finalized Dose Escalation/Dose Exploration Trial in 77 R/R AML PatientsFavorable safety with monotherapy responses across four dose levels with no DLT in mutationally diverse and difficult to treat...
Aptose Biosciences Provides Update on Reverse Stock Split
June 05, 2023 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, June 05, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023
May 31, 2023 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 31, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Enters into $25 Million Committed Equity Facility
May 25, 2023 16:14 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 25, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders
May 23, 2023 17:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 23, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Reports Results for the First Quarter 2023
May 08, 2023 16:01 ET
|
Aptose Biosciences, Inc.
─ Tuspetinib Dose Escalation and Dose Exploration Trial Completed and Delivered Clinical Responses as Monotherapy Over Four Dose Levels in Very Difficult to Treat AML Patient Populations ─ ─ Doublet...
Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference
May 04, 2023 07:01 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 04, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted...
Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023
April 24, 2023 07:01 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, April 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral...